[HTML][HTML] LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
K Westendorf, S Žentelis, L Wang, D Foster… - Cell reports, 2022 - cell.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
K Westendorf, S Žentelis, L Wang, D Foster… - 2022 - agris.fao.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …
[引用][C] LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
K Westendorf, S Žentelis, L Wang, D Foster… - Cell Reports, 2022 - cir.nii.ac.jp
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants | CiNii Research CiNii
国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
K Westendorf, S Žentelis, L Wang, D Foster… - Cell …, 2022 - pubmed.ncbi.nlm.nih.gov
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.
K Westendorf, S Žentelis, L Wang, D Foster… - Cell Reports, 2022 - europepmc.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …
[PDF][PDF] LY-CoV1404 potently neutralizes SARS-CoV-2 variants
K Westendorf, S Žentelis, D Foster, P Vaillancourt… - academia.edu
LY-CoV1404 is a highly potent, neutralizing, SARS-CoV-2 spike glycoprotein receptor
binding domain (RBD)-specific antibody identified from a convalescent COVID-19 patient …
binding domain (RBD)-specific antibody identified from a convalescent COVID-19 patient …
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
K Westendorf, L Wang, S Žentelis, D Foster… - bioRxiv, 2021 - biorxiv.org
SARS-CoV-2 neutralizing monoclonal antibodies (mAbs) can reduce the risk of
hospitalization when administered early during COVID-19 disease. However, the …
hospitalization when administered early during COVID-19 disease. However, the …
[HTML][HTML] LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
K Westendorf, S Žentelis, L Wang, D Foster… - Cell Reports, 2022 - Elsevier
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …
[HTML][HTML] LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
K Westendorf, S Žentelis, L Wang, D Foster… - Cell Reports, 2022 - ncbi.nlm.nih.gov
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
K Westendorf, S Žentelis, L Wang, D Foster… - Cell …, 2022 - researchexperts.utmb.edu
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …